TLX Telix Pharmaceuticals Limited - American Depositary Shares
NASDAQ · View on SEC EDGAR ↗ close Oct 5, 2026 10-K/10-Q Mar 20, 2026
$10.88
· of 52w range
· above low
· to high
$6.2852w low
$13.1152w high
P/E
-355.0
EPS
$-0.02
Revenue
$804M
your badges
52W Range
$6–$13
Analyst Rating
·
Price Target
$20
P/E
-355.0
ROE
-1.8%
Net Profit Margin
-0.89%
Your badge strip is empty — pin a metric anywhere on this page.
TLX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$10.88
P/E
-355.0
EPS
$-0.02
Revenue
$804M
ROE
-1.8%
52W Range
$6–$13
TLX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$804M2022-12-31 → 2025-12-31
EPS$-0.022022-12-31 → 2025-12-31
Free Cash Flow$-43M2024-12-31 → 2025-12-31
Net margin-0.89%2024-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | TLX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -355.0 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | TLX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Gross Margin | 53.0% | · | · | · | |
| Operating Margin | 3.7% | · | · | · | |
| EBITDA Margin | 6.4% | · | · | · | |
| Pretax Margin | -0.66% | · | · | · | |
| Net Profit Margin | -0.89% | · | · | · | |
| ROA | -0.68% | · | · | · | |
| ROE | -1.8% | · | · | · | |
| ROIC | 9.7% | · | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | TLX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio | 1.4 | · | · | · | |
| Quick Ratio | 1.2 | · | · | · | |
| Interest Coverage | 164.5 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | TLX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.8 | · | · | · | |
| Inventory Turnover | 12.4 | · | · | · | |
| Receivables Turnover | 7.4 | · | · | · | |
| Revenue / Employee | ≈$717.7K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $804M | $517M | $333M | |
| Cost of Revenue | $377M | $180M | $123M | |
| Gross Profit | $426M | $336M | $210M | |
| R&D Expense | $171M | $128M | $85M | |
| SG&A Expense | $96M | $85M | $50M | |
| Operating Income | $30M | $55M | $11M | |
| Interest Expense | $181.0K | $64.0K | $97.0K | |
| Interest Income | $6M | $7M | $671.0K | |
| Pretax Income | $-5M | $38M | $3M | |
| Income Tax | $2M | $4M | $-2M | |
| Net Income | $-7M | $34M | $4M | |
| EPS (Basic) | $-0.02 | $0.10 | $0.01 | |
| EPS (Diluted) | $-0.02 | $0.10 | $0.01 | |
| Shares (Basic) | 337,880,000 | 331,226,000 | 319,181,000 | |
| Shares (Diluted) | 337,880,000 | 345,188,000 | 323,710,000 | |
| EBITDA | $51M | $90M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $142M | $440M | $84M | |
| Receivables | $129M | $87M | $44M | |
| Inventory | $37M | $24M | $13M | |
| Current Assets | $330M | $570M | $159M | |
| PP&E (Net) | $59M | $28M | $16M | |
| Goodwill | $199M | $67M | · | |
| Intangibles | $593M | $258M | $110M | |
| Total Assets | $1.16B | $940M | $277M | |
| Accounts Payable | $150M | $87M | $54M | |
| Current Liabilities | $232M | $205M | $111M | |
| Total Liabilities | $749M | $587M | $175M | |
| Retained Earnings | $-155M | $-153M | $-187M | |
| Stockholders' Equity | $415M | $353M | $103M |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| D&A | $22M | $5M | $4M | |
| Other Non-cash | $-32M | $-15M | · | |
| Operating Cash Flow | $-17M | $27M | $14M | |
| CapEx | $26M | $9M | $6M | |
| Investing Cash Flow | $-286M | $-87M | $-17M | |
| Financing Cash Flow | $-4M | $417M | $7M | |
| Free Cash Flow | $-43M | $29M | · | |
| Levered FCF | $-43M | $29M | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Gross Margin | 53.0% | 65.1% | · | |
| Operating Margin | 3.7% | 10.5% | · | |
| Net Margin | -0.89% | 6.4% | · | |
| Pretax Margin | -0.66% | 7.2% | · | |
| EBITDA Margin | 6.4% | 11.5% | · | |
| ROA | -0.68% | 5.6% | · | |
| ROE | -1.8% | 14.9% | · | |
| ROIC | 9.7% | 12.9% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Current Ratio | 1.4 | 2.8 | · | |
| Quick Ratio | 1.2 | 2.6 | · | |
| Interest Coverage | 164.5 | 1001.6 | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.9 | · | |
| Inventory Turnover | 12.4 | 10.8 | · | |
| Receivables Turnover | 7.4 | 8.5 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue / Share | $2.38 | $2.27 | · | |
| Cash Flow / Share | $-0.05 | $0.12 | · | |
| EPS (TTM) | $-0.02 | $0.10 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue TTM | $804M | $517M | · | |
| Net Income TTM | $-7M | $34M | · | |
| P/E | -355.0 | 157.8 | · | |
| Earnings Yield | -0.28% | 0.63% | · |
Per Share
| Metric | Trend | Q4 2025 |
|---|---|---|
| EPS (TTM) | $-0.02 |
Valuation (TTM)
| Metric | Trend | Q4 2025 |
|---|---|---|
| Revenue TTM | $804M | |
| Net Income TTM | $-7M | |
| P/E | -355.0 | |
| Earnings Yield | -0.28% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | $804M | $517M | $333M | $160M |
| Gross Margin % | 53.0% | 65.1% | · | · |
| Operating Margin % | 3.7% | 10.5% | · | · |
| Net Income | $-7M | $34M | $4M | $-104M |
| Diluted EPS | $-0.02 | $0.10 | $0.01 | $-33.50 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Current Ratio | 1.4 | 2.8 | · | · |
| Quick Ratio | 1.2 | 2.6 | · | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-43M | $29M | · | · |
Institutional owners (13F) 61 filers · $34.4M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
61
Value held
$34.4M
New positions
23
Exited positions
1
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 23 (+12 vs prior Q) | 1 (-10 vs prior Q) | 20 (+3 vs prior Q) | 8 (0 vs prior Q) | +458K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| FMR LLC | $6,470,702 | 561,206 | 18.79% | Shares |
| LAZARD ASSET MANAGEMENT LLC | $3,276,907 | 284,207 | 9.51% | Shares |
| PORTLAND INVESTMENT COUNSEL INC. | $3,069,286 | 266,200 | 8.91% | Shares |
| Private Advisor Group, LLC | $2,274,324 | 197,250 | 6.60% | Shares |
| MARSHALL WACE, LLP | $2,181,339 | 189,188 | 6.33% | Shares |
| MORGAN STANLEY | $1,913,728 | 165,978 | 5.56% | Shares |
| Integrated Wealth Concepts LLC | $1,895,497 | 164,397 | 5.50% | Shares |
| UBS Group AG | $1,553,068 | 134,698 | 4.51% | Shares |
| BLAIR WILLIAM & CO/IL | $1,418,017 | 122,985 | 4.12% | Shares |
| Raiffeisen Bank International AG | $1,299,500 | 115,000 | 3.77% | Shares |
| Quadrature Capital Ltd | $1,180,960 | 102,425 | 3.43% | Shares |
| JPMORGAN CHASE & CO | $876,185 | 77,538 | 2.54% | Shares |
| XY Capital Ltd | $821,985 | 71,291 | 2.39% | Shares |
| XTX Topco Ltd | $792,987 | 68,776 | 2.30% | Shares |
| Vanguard Personalized Indexing Management, LLC | $680,143 | 58,989 | 1.97% | Shares |
| NLB Skladi, upravljanje premozenja, d.o.o. | $668,740 | 58,000 | 1.94% | Shares |
| Mariner, LLC | $427,593 | 37,085 | 1.24% | Shares |
| Capricorn Fund Managers Ltd | $416,233 | 36,100 | 1.21% | Shares |
| GTS SECURITIES LLC | $409,742 | 35,537 | 1.19% | Shares |
| JANE STREET GROUP, LLC | $384,975 | 33,389 | 1.12% | Shares |
| IHT Wealth Management, LLC | $372,366 | 32,295 | 1.08% | Shares |
| SummitTX Capital, L.P. | $364,590 | 31,621 | 1.06% | Shares |
| Portolan Capital Management, LLC | $293,139 | 25,424 | 0.85% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $236,549 | 20,516 | 0.69% | Shares |
| HSBC HOLDINGS PLC | $190,436 | 16,488 | 0.55% | Shares |
| Orion Porfolio Solutions, LLC | $180,076 | 15,618 | 0.52% | Shares |
| Vident Advisory, LLC | $137,841 | 11,955 | 0.40% | Shares |
| BANK OF AMERICA CORP /DE/ | $127,037 | 11,018 | 0.37% | Shares |
| NATIXIS | $126,928 | 10,999 | 0.37% | Shares |
| TWO SIGMA INVESTMENTS, LP | $117,986 | 10,233 | 0.34% | Shares |
| RHUMBLINE ADVISERS | $91,287 | 7,918 | 0.27% | Shares |
| Arax Advisory Partners | $24,821 | 2,152 | 0.07% | Shares |
| Clearstead Advisors, LLC | $24,351 | 2,112 | 0.07% | Shares |
| NewEdge Advisors, LLC | $22,138 | 1,920 | 0.06% | Shares |
| OSAIC HOLDINGS, INC. | $17,745 | 1,539 | 0.05% | Shares |
| ROYAL BANK OF CANADA | $17,000 | 1,500 | 0.05% | Shares |
| CWM, LLC | $13,637 | 1,425 | 0.04% | Shares |
| BlackRock, Inc. | $12,216 | 1,060 | 0.04% | Shares |
| EverSource Wealth Advisors, LLC | $11,023 | 956 | 0.03% | Shares |
| Larson Financial Group LLC | $10,365 | 899 | 0.03% | Shares |
| JONES FINANCIAL COMPANIES LLLP | $9,477 | 889 | 0.03% | Shares |
| Blue Trust, Inc. | $8,555 | 742 | 0.02% | Shares |
| Aspect Partners, LLC | $4,624 | 401 | 0.01% | Shares |
| GAMMA Investing LLC | $3,205 | 278 | 0.01% | Shares |
| ASSETMARK, INC | $2,133 | 185 | 0.01% | Shares |
| SIGNATUREFD, LLC | $1,706 | 148 | 0.00% | Shares |
| CVA Family Office, LLC | $1,464 | 127 | 0.00% | Shares |
| Parallel Advisors, LLC | $1,158 | 100 | 0.00% | Shares |
| Ameritas Advisory Services, LLC | $1,038 | 90 | 0.00% | Shares |
| NISA INVESTMENT ADVISORS, LLC | $1,015 | 88 | 0.00% | Shares |
Company insiders 2 insiders · 2 officers · 1 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Christian Behrenbruch | MD & Group CEO | April 29, 2026 P | 20,742,935 | 2 | 0 | $996,738 |
| Darren Charlton Smith | Group Chief Financial Officer | Sept. 7, 2026 P | 13,992 | 1 | 0 | $20,006 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 34 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| PIZ · Invesco Exchange-Traded Fund Trust … | 0.54% | 28,315 SH | Oct. 2, 2026 | Daily |
| IDLV · Invesco Exchange-Traded Fund Trust … | 0.44% | 10,641 SH | Oct. 2, 2026 | Daily |
| EWG · iShares, Inc. | 0.43% | 52,435 SH | Sept. 11, 2026 | Daily |
| EUFN · iShares Trust | 0.23% | 68,497 SH | Sept. 11, 2026 | Daily |
| IDHQ · Invesco Exchange-Traded Fund Trust … | 0.11% | 9,006 SH | Oct. 2, 2026 | Daily |
| EZU · iShares, Inc. | 0.11% | 74,646 SH | Sept. 11, 2026 | Daily |
| ISCF · iShares Trust | 0.09% | 51,629 SH | Sept. 11, 2026 | Daily |
| SCZ · iShares Trust | 0.09% | 983,580 SH | Sept. 11, 2026 | Daily |
| IQLT · iShares Trust | 0.09% | 90,173 SH | Sept. 11, 2026 | Daily |
| DMXF · iShares Trust | 0.08% | 5,169 SH | Sept. 11, 2026 | Daily |
| EFV · iShares Trust | 0.07% | 168,927 SH | Sept. 11, 2026 | Daily |
| IEUR · iShares Trust | 0.05% | 35,884 SH | Sept. 11, 2026 | Daily |
| IVLU · iShares Trust | 0.05% | 16,976 SH | Sept. 11, 2026 | Daily |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.05% | 144,626 SH | Aug. 19, 2026 | Daily |
| IEFA · iShares Trust | 0.05% | 2,553,412 SH | Sept. 11, 2026 | Daily |
| IDEV · iShares Trust | 0.04% | 428,064 SH | Sept. 11, 2026 | Daily |
| VYMI · VANGUARD WHITEHALL FUNDS | 0.04% | 71,346 SH | Aug. 19, 2026 | Daily |
| EFA · iShares Trust | 0.04% | 222,732 SH | Sept. 11, 2026 | Daily |
| PABD · iShares Trust | 0.03% | 785 SH | Sept. 11, 2026 | Daily |
| IPAC · iShares Trust | 0.03% | 76,837 SH | Sept. 11, 2026 | Daily |
| VXUS · VANGUARD STAR FUNDS | 0.03% | 4,984,468 SH | Aug. 19, 2026 | Daily |
| VEU · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.03% | 793,641 SH | Aug. 19, 2026 | Daily |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0.03% | 3,332,164 SH | Aug. 19, 2026 | Daily |
| VSGX · VANGUARD WORLD FUND | 0.03% | 68,226 SH | Aug. 19, 2026 | Daily |
| WSML · iShares Trust | 0.03% | 15,936 SH | Sept. 11, 2026 | Daily |
| IXUS · iShares Trust | 0.03% | 496,295 SH | Sept. 11, 2026 | Daily |
| ACWX · iShares Trust | 0.02% | 19,976 SH | Sept. 11, 2026 | Daily |
| PXF · Invesco Exchange-Traded Fund Trust … | 0.02% | 4,864 SH | Oct. 2, 2026 | Daily |
| VPL · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.02% | 298,322 SH | Aug. 19, 2026 | Daily |
| IMFL · Invesco Exchange-Traded Self-Indexe… | 0.02% | 1,550 SH | Oct. 2, 2026 | Daily |
| TOK · iShares Trust | 0.01% | 175 SH | Sept. 11, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 280,885 SH | Aug. 19, 2026 | Daily |
| URTH · iShares, Inc. | 0.01% | 5,363 SH | Sept. 11, 2026 | Daily |
| ACWI · iShares Trust | 0.01% | 14,789 SH | Sept. 11, 2026 | Daily |
TLX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
4 analysts · 2026-10-01Mean target $19.59 +80.1%
← Below all targets
Current price $10.88
Low$15.41
Mean$19.59
High$21.53
Latest News Recent headlines mentioning this company
Telix (TLX) to Buy Germany’s ITM for up to $2.35 Billion to Lock in its Cancer Isotope Supply
Yahoo Finance · 1 week, 4 days ago
Regeneron Pharmaceuticals (REGN) Announces Collaboration With Telix Pharmaceuticals Limited
Yahoo Finance · 5 months, 2 weeks ago
Regeneron Pharma Partners Telix Pharma To Jointly Develop Radiopharmaceutical Therapies
Nasdaq · 5 months, 3 weeks ago
Telix And Regeneron Partner To Advance Next-Generation Radiopharmaceutical Therapies
Nasdaq · 5 months, 3 weeks ago
Telix Pharmaceuticals Q1 Group Revenue Rises; Stock Up
Nasdaq · 5 months, 4 weeks ago
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 20-F/A filed Mar 20, 2026